title: Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.
abstract: Arsenic trioxide (As2O3) with or without interferon-a (IFN) was given to 4 patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATLL). Treatment with As2O3 and IFN showed an encouraging response in two moderately-aggressive ATLL patients, while As2O3 alone was ineffective in two patients with very aggressive and rapidly progressing ATLL. Further studies are needed to clarify the role of As2O3 and its usefulness when combined with IFN for the treatment of ATLL.
authors.forename: Kenji
authors.initials: K
authors.lastname: Ishitsuka
authors.forename: Junji
authors.initials: J
authors.lastname: Suzumiya
authors.forename: Mikiko
authors.initials: M
authors.lastname: Aoki
authors.forename: Kentaro
authors.initials: K
authors.lastname: Ogata
authors.forename: Shuuji
authors.initials: S
authors.lastname: Hara
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tamura
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000627:therapeutic use*; D045744:Cell Line, Tumor / Q000187:drug effects; D018450:Disease Progression; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010087:Oxides / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D016879:Salvage Therapy; D013921:Thrombocytopenia / Q000188:drug therapy / Q000209:etiology
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D016898:Interferon-alpha; D010087:Oxides; D000077237:Arsenic Trioxide